How does the efficacy and safety of Oralair® compare to other products on the market?
Désirée Larenas-Linnemann Pediatric Allergy and Asthma Clinic, Department of Investigation, Hospital Médica Sur, México City, México Abstract: Due to differences between allergen immunotherapy (AIT) trials in patient populations, trial design (i...
Saved in:
Main Author: | Larenas-Linnemann D (Author) |
---|---|
Format: | Book |
Published: |
Dove Medical Press,
2016-05-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
ORALAIR: A novel sublingual immunotherapy
by: Arpita Singh, et al.
Published: (2016) -
Update about Oralair® as a treatment for grass pollen allergic rhinitis
by: L. Klimek, et al.
Published: (2022) -
Long-term efficacy, safety and durability of Juvéderm® XC
by: Ballin AC, et al.
Published: (2013) -
Cost-effectiveness analysis of Mammostrat® compared with Oncotype DX® to inform the treatment of breast cancer
by: Mislick K, et al.
Published: (2014) -
Examining the efficacy, safety, and patient acceptability of the combined contraceptive vaginal ring (NuvaRing®)
by: Devorah R Wieder, et al.
Published: (2010)